Collegium Pharmaceutical, Inc.

AI-generated fair value estimate for this company.

Method: 10-year levered equity FCF DCF: $300M normalized equity FCF base (vs. $327.6M FY2025 actual); +5% growth years 1-2, -8% years 3-5 (anticipated loss-of-exclusivity risk on the core pain portfolio), -10% years 6-10, 0% terminal growth; 13% cost of equity (reflecting the approximately $1.22B debt load); 32.56M shares outstanding; no separate net-debt subtraction since the FCF base is already net of interest expense.

Reasoning: Collegium generates very strong free cash flow today, but its revenue is concentrated in a pain-portfolio (Xtampza ER/Nucynta franchise) facing future generic and exclusivity risk, so a 'melting ice cube' profile with a steep multi-year decline phase was modeled rather than perpetual growth, with a higher discount rate to reflect the leverage from debt-funded acquisitions.